查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1950518

按設備類型、技術和最終用途分類的全球卵子收集設備市場預測（2026-2032年）

Oocyte Collectors Market by Collector Type, Technology, End Use - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 188 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2025年卵子收集設備市場價值為2,931萬美元，預計到2026年將成長至3,275萬美元，年複合成長率為4.61%，到2032年將達到4019萬美元。

關鍵市場統計數據
基準年 2025 2931萬美元
預計年份：2026年 3275萬美元
預測年份 2032 4019萬美元
複合年成長率 (%) 4.61%

權威的卵子採集設備指南，說明了臨床應用、設備類別、相關人員的優先事項，以及這些因素如何影響採購決策。

卵子採集裝置在輔助生殖中發揮核心作用，連接著不孕症、醫院和研究環境中的臨床和醫療設備工程。這些裝置能夠實現精準的卵子採集，減少操作差異，並提高檢體完整性。因此，它們很容易受到臨床醫生偏好變化、滅菌通訊協定演變以及自動化技術進步的影響。本介紹將闡明臨床背景，定義裝置類型，並指出影響採購和實施決策的關鍵相關人員。

技術創新、滅菌標準和系統級整合如何重塑卵子採集實務中的產品開發和臨床應用

受技術創新、日益嚴格的感染防治法規以及醫療機構採購政策變化的影響，卵子採集設備的市場格局正經歷多重變革。自動化程度的提高正在重新定義使用者的期望，可程式設計的工作流程，從而提高抽吸模式的一致性並減少操作人員的差異。同時，對滅菌化學和可重複使用設備生命週期管理的日益重視，迫使製造商重新思考材料和服務模式，並透過耐用性和檢驗的清潔流程創造新的差異化機會。

美國近期加徵關稅對卵子收集設備相關人員的採購、製造地、籌資策略和供應鏈韌性的影響

美國近期關稅調整正在改變醫療設備供應鏈的成本結構，對卵子採集設備製造商、經銷商和終端用戶都產生了實際的影響。關稅影響採購、零件在地採購和庫存策略的決策，促使一些供應商重新評估其供應組合併探索其他製造地。因此，採購機構面臨對到岸成本、前置作業時間和供應商韌性的更嚴格審查，這影響合約談判和資本規劃。

將採集器類型、自動化程度和最終使用環境與購買行為、臨床工作流程和商業化策略連結起來的精確細分分析

對市場區隔的詳細分析揭示了設備設計、自動化程度和使用環境將如何影響採購優先順序和市場接受度曲線。根據收集器類型，市場可分為一次性使用和可重複使用兩類。可重複使用產品可進一步分為高壓釜及化學滅菌型。這種區分至關重要，因為一次性解決方案強調一次性使用的無菌性和簡化的物流，而可重複使用方案則以較低的前期資本投入和更複雜的滅菌流程為代價，換取了更低的單次手術材料成本和潛在的廢物排放減少。製造商和醫療系統在選擇這些方案時，必須考慮生命週期通訊協定、滅菌驗證和材料相容性。

區域需求模式和監管差異決定了美洲、歐洲、中東和非洲以及亞太地區的市場進入和商業化策略的差異化。

區域趨勢造就了不同的需求促進因素和應用模式，反映了當地的臨床基礎設施、法規結構和採購重點。在美洲，應用主要集中在專業的生育中心和綜合醫院系統，買家關注設備的可靠性、滅菌能力和供應商的應對力。歐洲、中東和非洲地區的市場結構較為複雜，有些國家擁有完善的管理體制，而有些國家的輔助生殖基礎設施則相對低度開發，這為靈活的產品供應和分級支援模式創造了機會。亞太地區涵蓋了廣泛的臨床環境和快速成長的生育服務，因此，擴充性、成本效益和本地化生產夥伴關係對於市場准入和擴張至關重要。

由產品創新、臨床檢驗、服務生態系統和策略聯盟驅動的競爭格局將決定產品在臨床環境中的採用和保留。

卵子採集領域的競爭格局取決於設備創新、服務生態系統和臨床可靠性之間的平衡。領先的製造商透過投資可用性研究、滅菌檢驗和整合能力，建立臨床信任並與高運作的醫療機構建立長期合作關係。新參與企業通常透過追求細分市場差異化來站穩腳跟，例如低成本的一次性產品、先進的自動化模組和易於滅菌的材料；而現有供應商則利用其成熟的分銷網路和臨床證據來捍衛市場佔有率，並向綜合生殖健康產品組合進行交叉銷售。

針對製造商和經銷商的高影響力策略行動，旨在加速設備採用、降低供應鏈風險並建立可防禦的競爭優勢。

產業領導者應採取一系列切實可行的措施，以鞏固市場地位、推動產品普及並降低外部風險。首先，應優先考慮模組化產品架構和檢驗的滅菌途徑，並設計可相容於一次性使用和可重複使用工作流程的設備，以滿足多樣化的客戶需求，同時簡化監管申報流程。其次，應投資於自動化能力，以提高操作的可重複性並降低對操作人員的依賴性，同時輔以完善的培訓模組和模擬程序，以縮短臨床醫生的學習曲線。

該研究透過透明的多來源調查方法檢驗了研究結果，該方法結合了臨床環境中的面對面訪談、程序觀察和嚴格的文獻綜述。

本研究結合一手資料和二手資料，全面涵蓋了臨床、技術和商業性方面。一手資料包括對臨床醫生、採購經理和醫療設備技術人員進行結構化訪談，以及與消毒專業人員和檢查室管理人員進行面對面交流，以了解操作流程。此外，還對典型的生育診所和檢查室環境中的手術流程和設備操作進行了觀察性研究，以檢驗使用者體驗和培訓需求。

綜合各項策略需求表明，檢驗的滅菌流程、自動化實施以及區域一致性將決定未來的臨床和商業性成功。

總之，卵子採集設備的市場環境將由臨床需求、滅菌需求、自動化進展、區域性採購模式等因素交互作用決定。那些能夠使產品設計與檢驗的滅菌流程相匹配、投資於可重複的自動化技術並採取符合區域特徵的商業性相關人員的利益相關者，將最有利於贏得臨床信任並實現長期市場應用。同時，供應鏈的韌性以及積極應對關稅造成的成本波動策略對於保護利潤和維持服務水準至關重要。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 按收集器類型分類的卵子收集設備市場

  • 一次性
  • 可重複使用的
    • 高壓釜滅菌
    • 化學可滅菌

第9章卵子器市場：依技術分類

  • 自動的
  • 手動的
  • 半自動

第10章卵子設備市場：依最終用途分類

  • 不孕不育診所
  • 醫院
  • 研究所

第11章卵子收集裝置市場：依地區分類

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第12章卵子收集設備市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第13章 各國卵子收集設備市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第14章：美國卵子收集設備市場

第15章 中國集卵子設備市場

第16章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Boston IVF, Inc.
  • CARE Fertility Group Limited
  • Colorado Center for Reproductive Medicine, LLC
  • Corning Incorporated
  • Eppendorf AG
  • Fertility Partners, Inc.
  • Genea Biomedx Pty Ltd
  • Gynotec BV
  • IMV Technologies
  • IVFtech ApS
  • IVI RMA Global SL
  • Kitazato Corporation
  • Labotect GmbH
  • Monash IVF Group Limited
  • Nidacon International AB
  • Nikon Corporation
  • Olympus Corporation
  • PHC Holdings Corporation
  • Reprofit International as
  • Rocket Medical plc
  • Shady Grove Fertility Center, LLC
  • Smiths Medical（Smiths Group plc）
  • Sysmex Corporation
  • Terumo Corporation
  • The Baker Company, Inc.
  • Virtus Health Limited
Product Code: MRR-4F7A6D4FD8B5

The Oocyte Collectors Market was valued at USD 29.31 million in 2025 and is projected to grow to USD 32.75 million in 2026, with a CAGR of 4.61%, reaching USD 40.19 million by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 29.31 million
Estimated Year [2026] USD 32.75 million
Forecast Year [2032] USD 40.19 million
CAGR (%) 4.61%

An authoritative orientation to oocyte collectors describing clinical roles, device categories, stakeholder priorities, and how these elements converge to shape procurement decisions

Oocyte collectors are central to assisted reproductive procedures, and their function bridges clinical technique and device engineering in fertility, hospital, and research settings. The devices enable precise retrieval of oocytes, reducing procedural variability and improving specimen integrity; as such, they are subject to evolving clinician preferences, sterilization protocols, and automation advances. This introduction establishes the clinical context, clarifies device typologies, and identifies the principal stakeholders who influence procurement and adoption decisions.

Clinicians prioritize reliability and ease of use during transvaginal oocyte retrieval, which drives demand for devices that offer consistent suction control, minimal trauma, and compatibility with existing assisted reproductive workflows. Concurrently, medical device engineers focus on materials, sterilization compatibility, and control systems that balance disposability and reusability. Health systems evaluate devices through the lens of operational efficiency, infection control, and total cost of ownership, linking procurement decisions to procedural volumes and regulatory compliance. Taken together, these forces create a dynamic landscape that requires nuanced understanding of device characteristics, clinical outcomes, and institutional constraints.

How technological innovation, sterilization standards, and system-level integration are redirecting product development and clinical adoption across oocyte collection practice

The landscape for oocyte collectors is undergoing several transformative shifts driven by technology, regulatory emphasis on infection prevention, and changing institutional procurement philosophies. Advances in automation are reshaping user expectations, enabling more consistent suction profiles and programmable workflows that reduce operator variability. At the same time, heightened attention to sterilization chemistry and reusable device lifecycle management has pushed manufacturers to rethink materials and service models, creating new opportunities for differentiation through durability and validated cleaning processes.

Additionally, integration of digital controls and modular interfaces is facilitating compatibility with broader laboratory information systems, which enhances traceability and quality assurance. These technological shifts are complemented by procedural trends: clinicians increasingly favor devices that reduce procedural time, improve specimen quality, and integrate seamlessly into assisted reproductive technology suites. As a result, manufacturers and clinical leaders must collaborate to align product roadmaps with evolving clinical protocols, ensuring both regulatory compliance and adoption in high-volume centers. In short, the sector's trajectory combines device innovation with a systems-level focus on sterility, repeatability, and digital interoperability.

Implications of recent United States tariffs on sourcing, manufacturing footprints, procurement strategies, and supply chain resilience for oocyte collector stakeholders

Recent tariff changes in the United States have altered cost dynamics across medical device supply chains, with tangible implications for manufacturers, distributors, and end users of oocyte collectors. Tariffs influence decisions about sourcing, component localization, and inventory strategy, prompting some suppliers to reassess supplier portfolios and seek alternative manufacturing bases. Consequently, organizations engaged in procurement face heightened scrutiny over landed costs, lead times, and supplier resilience, which in turn affects contract negotiations and capital planning.

In practical terms, procurement teams are prioritizing suppliers with diversified manufacturing footprints or established domestic production to mitigate tariff exposure and supply chain disruption. Meanwhile, manufacturers with global operations are accelerating localization of critical components or exploring tariff engineering strategies to minimize cost impacts. For clinical programs and research institutions, the immediate effect is more rigorous vendor evaluation and an increased willingness to consider total lifecycle costs rather than purchase price alone. As policy and trade environments continue to evolve, stakeholders must remain agile, updating sourcing strategies and contingency plans to preserve operational continuity and manage budgetary pressures.

Precise segmentation analysis linking collector type, automation tiers, and end-use environments to purchasing behavior, clinical workflows, and commercialization strategies

A granular view of segmentation reveals how device design, automation level, and use environment shape procurement priorities and adoption curves. Based on Collector Type, market is studied across Disposable and Reusable. The Reusable is further studied across Autoclavable and Chemical Sterilizable. This distinction matters because disposable solutions emphasize single-use sterility and simplified logistics, whereas reusable options trade higher upfront capital and sterilization workflows for lower per-procedure material expenditure and potentially reduced waste streams. Manufacturers and health systems must consider lifecycle protocols, sterilization validation, and material compatibility when selecting between these approaches.

Based on Technology, market is studied across Automatic, Manual, and Semi Automatic. The Automatic is further studied across Programmable and Robotic. The Manual is further studied across Capillary Tube and Suction Pump. The Semi Automatic is further studied across Air Pressure System and Electric Suction. Technology segmentation captures a spectrum from clinician-operated simplicity to fully automated systems that embed programmable parameters or robotic precision. Manual devices retain advantages in cost and familiarity, particularly in lower-volume settings, while automatic and semi-automatic options appeal to high-volume clinics seeking consistency, reduced operator fatigue, and integration with electronic recordkeeping. Robotic and programmable systems introduce higher capital and training demands but offer reproducibility that can standardize outcomes across operators.

Based on End Use, market is studied across Fertility Clinic, Hospital, and Research Institute. End-user segmentation underscores divergent purchasing criteria: fertility clinics often prioritize throughput, patient experience, and clinic-specific workflow integration; hospitals may emphasize cross-department utility, sterilization standards, and procurement policy alignment; research institutes place premium value on experimental flexibility, data capture capabilities, and compatibility with specialized laboratory equipment. Collectively, these segmentation lenses inform commercialization strategies, shaping pricing models, service offerings, and clinical support programs. As a result, vendors must craft differentiated value propositions that address sterilization pathways, automation preferences, and the specific procedural demands of each end-use environment.

Regional demand patterns and regulatory nuances across the Americas, Europe Middle East & Africa, and Asia-Pacific that dictate differentiated market entry and commercialization strategies

Regional dynamics create divergent demand drivers and adoption patterns that reflect local clinical infrastructures, regulatory frameworks, and procurement priorities. Americas exhibit concentrated adoption in specialized fertility centers and integrated hospital systems, with buyer attention on device reliability, sterilization throughput, and supplier responsiveness. Europe, Middle East & Africa show heterogenous markets where established regulatory regimes in some countries coexist with nascent assisted reproductive infrastructure in others, creating opportunities for flexible product offerings and tiered support models. Asia-Pacific encompasses a wide spectrum of clinical environments and rapidly growing fertility services, where scalability, cost-efficiency, and local manufacturing partnerships are major influences on market entry and expansion.

These geographic distinctions shape go-to-market approaches: in the Americas, emphasis on value-added services and clinical validation studies strengthens clinical adoption; across Europe, Middle East & Africa, regulatory navigation and tailored training programs determine pace of uptake; and in Asia-Pacific, strategic alliances with local distributors and manufacturing localization can significantly accelerate penetration. Understanding these regional nuances enables manufacturers and suppliers to prioritize deployments, align training and after-sales support, and adapt product features to meet distinct clinical and regulatory expectations.

Competitive dynamics driven by product innovation, clinical validation, service ecosystems, and strategic partnerships that determine adoption and retention in clinical settings

Competitive dynamics in the oocyte collectors domain are defined by a balance between device innovation, service ecosystems, and clinical credibility. Leading manufacturers invest in usability research, sterilization validation, and integration capabilities to establish clinical trust and long-term relationships with high-volume centers. New entrants often pursue niche differentiation-such as low-cost disposables, advanced automation modules, or sterilization-friendly materials-to gain an initial foothold, while incumbent suppliers leverage established distribution networks and clinical evidence to defend share and cross-sell to integrated reproductive health portfolios.

Partnerships with clinical opinion leaders and participation in multicenter procedural studies amplify product credibility and accelerate adoption, particularly for automated or semi-automated platforms that require changes in clinician technique. Meanwhile, aftermarket service and device maintenance programs influence purchasing decisions, as institutions weigh the benefits of warranty, rapid parts replacement, and training against capital expenditures. Ultimately, the competitive landscape rewards firms that combine technical robustness with comprehensive clinical support and clear evidence of improved procedural consistency or operational efficiency.

High-impact strategic actions for manufacturers and distributors to enhance device adoption, mitigate supply chain risk, and build defensible competitive differentiation

Industry leaders should adopt a set of actionable measures to secure market position, accelerate adoption, and mitigate external risks. First, prioritize modular product architectures and validated sterilization pathways so that devices can be configured for disposable or reusable workflows, meeting diverse customer requirements and simplifying regulatory submissions. Second, invest in automation features that improve reproducibility and reduce operator dependency, accompanied by robust training modules and simulation programs to shorten the clinician learning curve.

Third, diversify supply chains and consider selective localization of critical components to reduce exposure to tariff volatility and to shorten lead times. Fourth, strengthen clinical evidence through prospective usability and outcomes studies, focusing on metrics that matter to purchasers such as procedure time, specimen integrity, and reprocessing efficiency. Fifth, tailor commercial strategies by end-user segment and region, offering flexible pricing, leasing options, and bundled service agreements that align with procurement policies. By executing these priorities in a coordinated manner, manufacturers and distributors can enhance resilience, deepen clinical partnerships, and create defensible differentiation in a competitive landscape.

A transparent, multi-source research methodology combining firsthand clinical interviews, procedural observations, and rigorous literature review to validate insights

This research synthesizes primary and secondary inquiries to ensure comprehensive coverage of clinical, technical, and commercial dimensions. Primary inputs included structured interviews with practicing clinicians, procurement leaders, and device engineers, as well as direct consultations with sterilization specialists and laboratory managers to capture operational realities. These qualitative discussions were complemented by observational reviews of procedural workflows and device handling in representative fertility clinics and laboratory settings to validate user experience and training needs.

Secondary research encompassed peer-reviewed literature, regulatory guidance documents, device standards, and published clinical studies relevant to oocyte retrieval procedures and device sterilization. Data triangulation combined these multiple sources to identify consistent themes and reconcile divergent findings. Throughout the process, emphasis was placed on transparency in methodology, clear attribution of data sources, and iterative validation with subject-matter experts to ensure conclusions are both robust and actionable for decision-makers.

Synthesis of strategic imperatives showing how validated sterilization, automation adoption, and regional alignment will determine future clinical and commercial success

In closing, the oocyte collectors landscape is defined by the interplay of clinical requirements, sterilization imperatives, automation trajectories, and region-specific procurement patterns. Stakeholders who align product design with validated sterilization workflows, invest in reproducible automation, and adapt commercial approaches to regional nuances will be best positioned to capture clinical trust and long-term adoption. Concurrently, supply chain resilience and proactive strategies to manage tariff-driven cost dynamics are essential to protect margins and sustain service levels.

Moving forward, decision-makers should prioritize collaborations between clinical teams and product developers to co-create devices that fit procedural realities while delivering measurable improvements in consistency and efficiency. By focusing on validated performance, streamlined reprocessing, and flexible commercial models, manufacturers and health systems can drive improved outcomes and operational efficiency, ensuring that device advancement translates into tangible clinical benefit.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Oocyte Collectors Market, by Collector Type

  • 8.1. Disposable
  • 8.2. Reusable
    • 8.2.1. Autoclavable
    • 8.2.2. Chemical Sterilizable

9. Oocyte Collectors Market, by Technology

  • 9.1. Automatic
  • 9.2. Manual
  • 9.3. Semi Automatic

10. Oocyte Collectors Market, by End Use

  • 10.1. Fertility Clinic
  • 10.2. Hospital
  • 10.3. Research Institute

11. Oocyte Collectors Market, by Region

  • 11.1. Americas
    • 11.1.1. North America
    • 11.1.2. Latin America
  • 11.2. Europe, Middle East & Africa
    • 11.2.1. Europe
    • 11.2.2. Middle East
    • 11.2.3. Africa
  • 11.3. Asia-Pacific

12. Oocyte Collectors Market, by Group

  • 12.1. ASEAN
  • 12.2. GCC
  • 12.3. European Union
  • 12.4. BRICS
  • 12.5. G7
  • 12.6. NATO

13. Oocyte Collectors Market, by Country

  • 13.1. United States
  • 13.2. Canada
  • 13.3. Mexico
  • 13.4. Brazil
  • 13.5. United Kingdom
  • 13.6. Germany
  • 13.7. France
  • 13.8. Russia
  • 13.9. Italy
  • 13.10. Spain
  • 13.11. China
  • 13.12. India
  • 13.13. Japan
  • 13.14. Australia
  • 13.15. South Korea

14. United States Oocyte Collectors Market

15. China Oocyte Collectors Market

16. Competitive Landscape

  • 16.1. Market Concentration Analysis, 2025
    • 16.1.1. Concentration Ratio (CR)
    • 16.1.2. Herfindahl Hirschman Index (HHI)
  • 16.2. Recent Developments & Impact Analysis, 2025
  • 16.3. Product Portfolio Analysis, 2025
  • 16.4. Benchmarking Analysis, 2025
  • 16.5. Boston IVF, Inc.
  • 16.6. CARE Fertility Group Limited
  • 16.7. Colorado Center for Reproductive Medicine, LLC
  • 16.8. Corning Incorporated
  • 16.9. Eppendorf AG
  • 16.10. Fertility Partners, Inc.
  • 16.11. Genea Biomedx Pty Ltd
  • 16.12. Gynotec B.V.
  • 16.13. IMV Technologies
  • 16.14. IVFtech ApS
  • 16.15. IVI RMA Global S.L.
  • 16.16. Kitazato Corporation
  • 16.17. Labotect GmbH
  • 16.18. Monash IVF Group Limited
  • 16.19. Nidacon International AB
  • 16.20. Nikon Corporation
  • 16.21. Olympus Corporation
  • 16.22. PHC Holdings Corporation
  • 16.23. Reprofit International a.s.
  • 16.24. Rocket Medical plc
  • 16.25. Shady Grove Fertility Center, LLC
  • 16.26. Smiths Medical (Smiths Group plc)
  • 16.27. Sysmex Corporation
  • 16.28. Terumo Corporation
  • 16.29. The Baker Company, Inc.
  • 16.30. Virtus Health Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL OOCYTE COLLECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL OOCYTE COLLECTORS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL OOCYTE COLLECTORS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. UNITED STATES OOCYTE COLLECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 11. CHINA OOCYTE COLLECTORS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL OOCYTE COLLECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY DISPOSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY DISPOSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY DISPOSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY AUTOCLAVABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY AUTOCLAVABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY AUTOCLAVABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY CHEMICAL STERILIZABLE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY CHEMICAL STERILIZABLE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY CHEMICAL STERILIZABLE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY AUTOMATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY AUTOMATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY AUTOMATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY MANUAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY MANUAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY MANUAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY SEMI AUTOMATIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY SEMI AUTOMATIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY SEMI AUTOMATIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY FERTILITY CLINIC, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY FERTILITY CLINIC, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY FERTILITY CLINIC, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY HOSPITAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY HOSPITAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY RESEARCH INSTITUTE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY RESEARCH INSTITUTE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY RESEARCH INSTITUTE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. AMERICAS OOCYTE COLLECTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 38. AMERICAS OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 39. AMERICAS OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 40. AMERICAS OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 41. AMERICAS OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 42. NORTH AMERICA OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 43. NORTH AMERICA OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 44. NORTH AMERICA OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 45. NORTH AMERICA OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 46. NORTH AMERICA OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 47. LATIN AMERICA OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. LATIN AMERICA OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 49. LATIN AMERICA OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 50. LATIN AMERICA OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 51. LATIN AMERICA OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 52. EUROPE, MIDDLE EAST & AFRICA OOCYTE COLLECTORS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 53. EUROPE, MIDDLE EAST & AFRICA OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 57. EUROPE OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. EUROPE OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 59. EUROPE OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 60. EUROPE OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 61. EUROPE OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 62. MIDDLE EAST OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 63. MIDDLE EAST OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 64. MIDDLE EAST OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 65. MIDDLE EAST OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 66. MIDDLE EAST OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 67. AFRICA OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 68. AFRICA OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. AFRICA OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 70. AFRICA OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 71. AFRICA OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 78. ASEAN OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 79. ASEAN OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 80. ASEAN OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 81. ASEAN OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 82. ASEAN OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 83. GCC OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GCC OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. GCC OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 86. GCC OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 87. GCC OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPEAN UNION OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPEAN UNION OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPEAN UNION OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPEAN UNION OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPEAN UNION OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 93. BRICS OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 94. BRICS OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 95. BRICS OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 96. BRICS OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 97. BRICS OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 98. G7 OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. G7 OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 100. G7 OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 101. G7 OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 102. G7 OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 103. NATO OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 104. NATO OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. NATO OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 106. NATO OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 107. NATO OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL OOCYTE COLLECTORS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. UNITED STATES OOCYTE COLLECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 110. UNITED STATES OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 111. UNITED STATES OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 112. UNITED STATES OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 113. UNITED STATES OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)
  • TABLE 114. CHINA OOCYTE COLLECTORS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 115. CHINA OOCYTE COLLECTORS MARKET SIZE, BY COLLECTOR TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. CHINA OOCYTE COLLECTORS MARKET SIZE, BY REUSABLE, 2018-2032 (USD MILLION)
  • TABLE 117. CHINA OOCYTE COLLECTORS MARKET SIZE, BY TECHNOLOGY, 2018-2032 (USD MILLION)
  • TABLE 118. CHINA OOCYTE COLLECTORS MARKET SIZE, BY END USE, 2018-2032 (USD MILLION)